Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medic
– Results from EV-103 trial evaluating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) in urothelial cancer to be featured as late-breaking oral session –BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its clinical development progra...
Source: pharmiweb.com